Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Temozolomide With Radiotherapy in Unresectable High Grade Gliomas
NCT03212742Phase 2Active, not recruiting
- Sponsor
- Centre François Baclesse
- Start
- Sep 2017
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in glioblastoma (GBM), sponsored by Centre François Baclesse. Started Sep 2017; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03212742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212742.